ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET.
The presentation will be available via a live webcast and an archived replay on the company website under Investors > Events and Presentations. The replay will be accessible for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ANIP gained 2.57%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ALVO -2.0%, HCM -2.41%, INDV +2.52%, AMRX +1.19%, SUPN +0.3%, suggesting today’s action is stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Strategic advisory council | Positive | -2.8% | Formed FutureVision Advisory Council for ophthalmology and retina franchise guidance. |
| Dec 01 | Board leadership change | Neutral | -0.5% | Orderly board chair transition framed around continuity and Rare Disease expansion. |
| Nov 25 | Conference presentation | Neutral | +2.8% | CEO fireside chat at Piper Sandler healthcare conference with webcast access. |
| Nov 11 | Conference presentation | Neutral | -1.4% | CEO fireside chat at Jefferies Global Healthcare Conference in London. |
| Nov 07 | Earnings and guidance | Positive | +0.2% | Record Q3 2025 results and raised 2025 revenue, EBITDA, and EPS guidance. |
Recent news has generally seen price reactions that align with the tone of announcements, with one notable divergence on a positive strategic update.
Over the past few months, ANI reported record Q3 2025 financial results and raised full-year guidance, followed by several investor conference appearances and governance initiatives. Earnings and most corporate events saw modestly aligned price moves, while the creation of the ophthalmology-focused FutureVision Advisory Council coincided with a short-term decline. Today’s J.P. Morgan Healthcare Conference presentation continues the pattern of active investor outreach and conference participation highlighted in late 2025.
Market Pulse Summary
This announcement highlights ANI’s participation in the high-profile J.P. Morgan Healthcare Conference, with a CEO presentation on January 13, 2026 and a webcast replay available for 30 days. It continues a pattern of active investor engagement following record Q3 2025 results and raised guidance. Investors typically monitor these events for incremental color on the Rare Disease franchise, capital allocation priorities, and how management frames longer-term growth drivers.
AI-generated analysis. Not financial advice.
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 30 days.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
E: ani@argotpartners.com
Media Relations:
Deborah Elson, Argot Partners
E: ani@argotpartners.com